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Movement Disorders (MD) are important in clinical neu-
rology because they are quite common. Understanding the
pathophysiology of MD requires understanding of the neu-
rochemical organisation of the basal ganglia (a complex of
five well interconnected subcortical nuclei). Clinicallly, the
basal ganglia disorders are recognized as movement disor-
ders and could be divided into the hypokinetic or akinetic-
rigid syndromes (characterized by slowness and difficulty in
generating voluntary movement) and the hyperkinetic
movement disorders (characterized by abnormal involun-
tary movements). In addition, nonmotor symptoms are in-
creasingly recognized as important determinant of Guality
of life (QoL) in MD. 
One of the best known MD, Parkinson’s disease (PD), was
the first disease of the brain where specific neurotransmitter
(dopamine) deficit was shown to be a major casual factor in
characteristic motor symptoms. Dopamine replacement
therapy became the first effective treatment and many drugs
for similar indications (DA agonists, MAO-B inhibitorsm
COMT inhibitors) as well as procedures (Deep brain stim-
ulation-DBS, Duodopa-duodenal infusion pump etc) have
been developed. The evidence-based medicine review will
be presented to update the field of MD therapy and high-
lights the current research of MD.
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